| __timestamp | BioMarin Pharmaceutical Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 10811000 |
| Thursday, January 1, 2015 | 402271000 | 33001000 |
| Friday, January 1, 2016 | 476593000 | 64936000 |
| Sunday, January 1, 2017 | 554336000 | 99909000 |
| Monday, January 1, 2018 | 604353000 | 127724000 |
| Tuesday, January 1, 2019 | 680924000 | 161524000 |
| Wednesday, January 1, 2020 | 737669000 | 182933000 |
| Friday, January 1, 2021 | 759375000 | 219982000 |
| Saturday, January 1, 2022 | 854009000 | 278139000 |
| Sunday, January 1, 2023 | 937300000 | 309799000 |
| Monday, January 1, 2024 | 1009025000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. BioMarin Pharmaceutical Inc. and Ultragenyx Pharmaceutical Inc., two prominent players in the industry, have shown distinct trajectories in their SG&A spending from 2014 to 2023. BioMarin's SG&A expenses have surged by over 200%, reflecting its aggressive expansion and market penetration strategies. In contrast, Ultragenyx, while also increasing its SG&A expenses by nearly 2800%, started from a much smaller base, indicating its rapid scaling efforts.
By 2023, BioMarin's SG&A expenses were approximately three times higher than Ultragenyx's, highlighting its established market presence. This comparison not only underscores the different growth stages of these companies but also offers insights into their strategic priorities. As the biotech landscape evolves, monitoring such financial metrics will be key to understanding industry dynamics.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.